In support with these findings, Shen et al. demonstrated that blocking the HMGB1–PARP1–LC3 nucleophagy axis restores chemosensitivity and enhances responses to PARP inhibitors in SCLC [33], highlighting a therapeutic synergy worth exploring clinically (Figure 2). Here, HMGB1 is linked to small cell lung carcinoma.